PACYLEX
Pacylex Pharmaceuticals develops a precision medicine solution for multiple common cancers. The company is developing a small molecule, oral chemotherapeutic, PCLX-001, to exploit this cancer mechanism by turning on selective lethality, apoptosis, in these cancer cells. The company's approach exploits a previously-unknown therapeutic target in cancer, making the drug a first-in-kind therapy. The diagnostic technology identifies those patients who will benefit from the drug, sparing many patients needless treatment. Pacylex Pharmaceuticals was founded on 2012 and is headquartered in Edmonton, Alberta, Canada.
PACYLEX
Industry:
Biotechnology Health Care Health Diagnostics Life Science Medical Pharmaceutical Therapeutics
Founded:
2012-01-01
Address:
Edmonton, Alberta, Canada
Country:
Canada
Website Url:
http://www.pacylex.com
Total Employee:
1+
Status:
Active
Contact:
1650-218-1840
Email Addresses:
[email protected]
Total Funding:
10.77 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Amazon Google Apps For Business ReCAPTCHA Cloudflare JS
Similar Organizations
Ritter Pharmaceuticals
Ritter Pharmaceuticals discovers and commercializes treatments for gastrointestinal diseases.
RainTree Oncology Services
RainTree Oncology Services provides oral drug acquisition and management services for patients with cancer.
Remedy Plan Therapeutics
Remedy Plan is a pre-clinical cancer therapeutics company developing first-in-class small molecule drugs that differentiate cancer cells.
Nia Therapeutics
Nia Therapeutics develops a precision neurostimulation therapy for the treatment of memory loss.
Versanis Bio
Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults.
Vetsource
Vetsource provides comprehensive solutions to those who care for pets - veterinarians and pet owners.
MultiplexDX Inc.
Developing products for precision medicine: affordable, reliable, specific, quantifiable, and accurate precision diagnostic technology.
Menten AI
Menten AI develops peptide and protein therapeutics using machine learning and quantum computing.
MindSciences
MindSciences develops and implements evidence-based mindfulness solutions that delight its customers.
MitoChem Therapeutics
MitoChem Therapeutics develops treatments to address the effects of mitochondrial dysfunction in neurodegenerative, aging, and disease.
MATTER
MATTER provides the healthcare industry with technology solutions to improve products and services.
2bPrecise
Precision medicine is rewriting the rules of health care. And 2bPrecise is rewriting the rules of precision medicine.
LakePharma
LakePharma is a biologics CRDMO that provides integrated solutions from discovery to engineering, development and GMP manufacturing.
LSK BioPharma
LSK BioPharma specializes in clinical development of promising therapies for unmet medical needs in cancer.
Actinium Pharmaceuticals
Actinium Pharmaceuticals develops alpha particle linked antibodies to treat cancer.
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Adastra Pharmaceuticals
Adastra Pharmaceuticals provides responsible solutions to advance patient care in oncology.
Abcuro
Abcuro develops first-in-class immunotherapies to treat autoimmunity and cancer.
Athos Therapeutics
Athos develops AI-based Precision Therapeutics for patients with Inflammatory Bowel, other Autoimmune Diseases, and cancer.
Amwise Diagnostic
Amwise Diagnostic is a leader in precision medicine technology for cancer.
Avitide
Avitide develops affinity purification solutions for biopharmaceutical companies.
Aptitude Medical Systems
Aptitude Medical Systems focuses on the potential of aptamers to solve the fundamental problems of antibodies.
Adial Pharmaceuticals
Adial Pharmaceuticals develops prescription medications for addiction and related disorders.
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Elephas
A live tumor imaging diagnostics company
Engrail Therapeutics
Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.
Epalex
Epalex is developing a novel inhaled treatment for epilepsy and migraine.
Elicio Therapeutics
Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.
BridgeBio Pharma
BridgeBio Pharma focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D.
Medical Guardian
Medical Guardian provides medical alert devices for seniors and peace of mind for their loved ones.
Flex Pharma
Flex Pharma develops clinically proven products and treatments for muscle cramps and spasms.
TCR2
TCR2 is a discovery stage pharmaceutical company that developed a unique proprietary TRuC™ platform.
Torigen Pharmaceuticals
Torigen Pharmaceuticals focuses on providing cancer care solutions for animals.
ThermaGenix
ThermaGenix is a polymerase chain reaction improvement company.
Quantason
Quantason develops bi-modal US/IDUS™ platform technology for diagnostic imaging and active screening.
Qiagen Suzhou Translational Medicine
A Chinese precision medicine solutions provider.
Kolltan Pharmaceuticals
Kolltan Pharmaceuticals develops new-generation monoclonal antibody oncology therapeutics.
Kezar Life Sciences
Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders
Kinnate Biopharma
Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers.
Woolsey Pharmaceuticals
Woolsey Pharmaceuticals specializes in reinventing ways to treat some of the world’s most challenging diseases.
SuperBrewed Food
SuperBrewed Food(formerlyWhite Dog Labs) is developing new probiotics for animals and human.
Sciety
Life science investor syndicate.
Sanguine
Sanguine develops innovative technology solutions for clinical researchers.
SinoVeda Canada
SinoVeda Canada develops high quality nutraceuticals and prescription pharmaceuticals from botanical sources.
Shanghai Ouyi Biomedical Technology
Shanghai Ouyi Biomedical Technology is a provider of gene sequencing services.
Diatech Pharmacogenetics
Diatech Pharmacogenetics is an Italian Precision Medicine company.
Assertio
Assertio is a pharmaceutical company focused on developing and commercializing products to treat pain and other.
ImmunoGenesis
ImmunoGenesis specializes in science-driven immune therapies for tumor treatment.
Glyscend
Glyscend develops a revolutionary approach to treating type 2 diabetes.
Genialis
Genialis tackles diseases of unmet need with in silico precision medicine, blending compbio & AI for translational & clinical discovery.
Vero Biotech
Vero Biotech is a biopharmaceutical company that commercializes inhaled nitric oxide delivery systems for healthcare providers.
Oncoceutics
Oncoceutics, Inc. is a drug discovery and development company targeting the most potent suppressor pathways in human cancer.
OncoDNA
OncoDNA is a company specialized in precision medicine for the treatment of cancer.
Oramed Pharmaceuticals
Oramed Pharmaceuticals develops proprietary Protein Oral Delivery technology for the delivery of drugs.
Cambridge Cancer Genomics
Cambridge Cancer Genomics develops precision oncology solutions to transform the way cancer patients are treated.
CytoImmune Therapeutics
CytoImmune Therapeutics develops novel, coordinated immunotherapy solutions for patients.
Cahaba Pharmaceuticals
Cahaba Pharmaceuticals develops novel therapeutics and supportive care products for cancer patients.
Padlock Therapeutics
Padlock is developing medicines targeting PADs, immune complexes in autoimmune diseases, and more.
PCI Pharma Services
PCI Pharma Services is a provider of outsourced services to the global pharmaceutical market.
PhAST Diagnostics
PhAST Diagnostics develops rapid diagnostic technology to provide actionable information on pathogens.
Psycheceutical
Psycheceutical is a patented delivery technology that provides safe bioavailable psychedelic pharmaceutical medicines.
Praxis Precision Medicines
Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.
Provenance Bio
Provenance Bio has developed a cutting edge synthetic biology platform to compete head-to-head with animal proteins, today making collagen.
Perceiv AI
AI-driven precision medicine, forecasting disease progression
Current Employees Featured
Founder
Investors List
Greenfire Bio
Greenfire Bio investment in Series A - Pacylex
VA Angels
VA Angels investment in Seed Round - Pacylex
Official Site Inspections
http://www.pacylex.com Semrush global rank: 5.97 M Semrush visits lastest month: 1.38 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 75.2.70.75
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Pacylex"
Team - Pacylex Pharmaceuticals
Explore the Pacylex Team & Advisory Board, the driving force behind our clinical-stage company. Our team and advisors are instrumental in our mission to transform cancer treatment for …See details»
Pacylex - Crunchbase Company Profile & Funding
Pacylex Pharmaceuticals develops a precision medicine solution for multiple common cancers. The company is developing a small molecule, oral chemotherapeutic, PCLX-001, to exploit …See details»
Pacylex Pharmaceuticals, Inc. - BioAlberta
Pacylex is developing PCLX-001, to selectively kill cancer cells while leaving normal cells unharmed. Animal tests show this drug eliminates tumors in leukemia and ... Director of TRIO …See details»
Pacylex Pharmaceuticals, Inc. | LinkedIn
Pacylex Pharmaceuticals, Inc. | 936 followers on LinkedIn. A new target in cancer care - triggering selective lethality with a new class of drugs. | Pacylex Pharmaceuticals is a clinical stage …See details»
Pacylex - Pacylex Pharmaceuticals Announces New Executive Team …
Jan 17, 2023 I am excited to be joining the company at this important time and look forward to helping Pacylex execute our objectives and scale our organization effectively.” Ms. Libonati …See details»
Pacylex Company Profile 2024: Valuation, Funding & Investors
Pacylex General Information Description. Developer of oral cancer therapy designed to treat blood and solid tumor cancers. The company's therapy attacks the membrane-associated proteins at …See details»
Pacylex Raises US $3.9 Million To Advance New Cancer Therapy …
Pacylex is developing an oral small molecule drug, PCLX-001, to treat cancers low in N-myristoyltransferase 2 (NMT2), a myristoylation enzyme whose deficiency is associated with …See details»
Pacylex - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Pacylex - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Pacylex . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 4. Contacts 3. ... Pacylex …See details»
Reportable
Pacylex Pharmaceuticals' Publishes a New Myristoylation Inhibitor Mechanism of Anti-Cancer Activity in Molecular Cancer Therapeutics Edmonton, Alberta, Canada October 10, 2024. …See details»
Pacylex - Pacylex Pharmaceuticals Closes Series A Funding to …
Pacylex has received regulatory authorization to begin clinical studies in Canada in the spring of 2021 in diffuse large B-cell lymphoma and solid tumors. Pacylex is also receiving support from …See details»
Pacylex Presents Updates on the Journey of PCLX-001 to the Clinic …
Jun 15, 2021 Edmonton, Alberta--(Newsfile Corp. - June 15, 2021) - On the heels of closing its Series A last month, Pacylex CEO Michael Weickert will present at The Biotechnology …See details»
Pacylex Granted FDA Fast Track Designation | Department of …
Nov 22, 2022 Edmonton, Alberta, Canada, November 22, 2022 Pacylex, a clinical-stage N-myristoyltransferase (NMT) inhibitor company developing first-in-class therapies for leukemia, …See details»
Health Canada Clears Pacylex Pharmaceuticals for New Phase 1 …
Pacylex expects to begin clinical studies in Canada in the spring of 2021 in diffuse large B-cell lymphoma and solid tumors. Contacts: Michael Weickert Ph.D 650-218-1840See details»
Pacylex - Pacylex Pharmaceuticals CEO Presents Zelenirstat for …
Apr 22, 2024 Today Pacylex announced that CEO Michael Weickert will present Phase 1 safety and efficacy results for zelenirstat and evidence supporting advancing it into clinical …See details»
Pacylex Pharmaceuticals Announces Publication in Current …
Mar 14, 2022 Edmonton, Alberta--(Newsfile Corp. - March 14, 2022) - Pacylex Pharmaceuticals, an oncology company developing a first-in-class, oral drug for a new approach to cancer …See details»
Pacylex - Pacylex Pharmaceuticals Recognized as BioAlberta’s …
Sep 27, 2024 Pacylex has exclusive rights to 503 small molecules NMTis, including 27 high potency compounds (IC50 <10nM) against human NMT1. Zelenirstat has advantages as an …See details»
Health Canada Approves PCLX-001 Phase I Clinical Trial - Pacylex
Pacylex News. Health Canada Approves PCLX-001 Phase I Clinical Trial. A No Objection Letter has been received from Health Canada on March 8, 2021, opening the way for a planned …See details»
PCLX 001, une avancée révolutionnaire dans la lutte contre le cancer
Feb 2, 2021 Les détails avec Luc Berthiaume, membre fondateur de Pacylex, la compagnie qui développe le médicament en produit thérapeutique. PCLX 001, une avancée révolutionnaire …See details»